LEADER 01430nam a2200349 i 4500 001 991000570279707536 005 20020503185904.0 008 991109s1998 it ||| | ita 020 $a8845309207$c25000 035 $ab10097156-39ule_inst 035 $aLE02518448$9ExL 040 $aFac. Economia$bita 082 0 $a330.973 082 0 $a331.1250973 100 1 $aSolow, Robert M.$077790 245 10$aInflazione, disoccupazione, politica monetaria /$cRobert M. Solow, John B. Taylor ; a cura e con un'introduzione di Benjamin M. Friedman 260 $a[Milano] :$bEtas Libri,$c1998 300 $aviii, 118 p. ;$c22 cm. 490 0 $aEconomia [Etas libri] 500 $aTrad. di Giuseppe Barile. 650 4$aDisoccupazione$zStati Uniti d'America 650 4$aInflazione$zStati Uniti d'America 650 4$aStati Uniti d'America$xPolitica monetaria 700 1 $aTaylor, John B. 740 0 $aInflation, unemployment and monetary policy 907 $a.b10097156$b17-02-17$c27-06-02 912 $a991000570279707536 945 $aLE025 ECO 330.9 SOL01.01$g1$i2025000067387$lle025$o-$pE0.00$q-$rl$s- $t0$u17$v6$w17$x0$y.i10113162$z27-06-02 945 $aLE025 ECO 330.9 SOL01.01$g2$i2025000067585$lle025$o-$pE0.00$q-$rl$s- $t0$u7$v9$w7$x0$y.i10113174$z27-06-02 996 $aInflazione, disoccupazione, politica monetaria$9196812 997 $aUNISALENTO 998 $ale025$b01-01-99$cm$da $e-$fita$git $h0$i2 LEADER 01092nam a2200241 i 4500 001 991003410279707536 008 080225s2005 sp 000 0 spa d 020 $a8472996654 035 $ab1368694x-39ule_inst 040 $aDip.to Studi Giuridici$bita 082 0 $a262.94 100 1 $aGarcia Failde, Juan Jose $0412815 245 10$aTratado de derecho procesal canonico :$b(Comentario al Codigo de derecho canonico vigente y a la Instruccion "Dignitas connubii" del 25 de enero de 2005 del Pontificio Consejo para los textos legislativos) /$cJuan Jose Garcia Failde 260 $aSalamanca :$bUniversidad Pontificia,$c2005 300 $a737 p. ;$c24 cm 440 0$aBibliotheca Salmanticensis.$pEstudios ;$v277 650 4$aDiritto processuale canonico 907 $a.b1368694x$b08-05-08$c25-02-08 912 $a991003410279707536 945 $aLE027 262.94 GAR01.01$g1$i2027000178285$lle027$o-$pE45.00$q-$rn$so $t0$u1$v0$w1$x0$y.i14747522$z08-05-08 996 $aTratado de derecho procesal canonico$91229533 997 $aUNISALENTO 998 $ale027$b25-02-08$cm$da $e-$fspa$gsp $h0$i0 LEADER 05335nam 2201153z- 450 001 9910557505703321 005 20220111 035 $a(CKB)5400000000044499 035 $a(oapen)https://directory.doabooks.org/handle/20.500.12854/76262 035 $a(oapen)doab76262 035 $a(EXLCZ)995400000000044499 100 $a20202201d2021 |y 0 101 0 $aeng 135 $aurmn|---annan 181 $ctxt$2rdacontent 182 $cc$2rdamedia 183 $acr$2rdacarrier 200 00$a3Ts in Gastrointestinal Microbiome Era: Technology, Translational Research and Transplant 210 $aBasel, Switzerland$cMDPI - Multidisciplinary Digital Publishing Institute$d2021 215 $a1 online resource (236 p.) 311 08$a3-0365-2796-6 311 08$a3-0365-2797-4 330 $aWe have entered a new era where some concepts of the complex community of microorganisms (microbiota comprising bacteria, fungi, viruses, bacteriophages and helminths) are being re-discovered and re-visited. Microbiota and human interaction is not new; they have shared a long history of co-existence. Nevertheless, the opportunities to understand the role of these microorganisms in human diseases and to design a potential treatment were limited. At present, thanks to development of innovative and cutting-edge molecular biological and microbiological technologies as well as clinical informatics and bioinformatics skills, microbiome application is moving into clinics. Approaches to therapy based on prebiotics, probiotics and lately on fecal microbiota transplantation has revolutionized medicine. Microbiota outnumbers our genes and is now regarded as another organ of the body. The gastrointestinal tract and gut microbiota display a well-documented symbiotic relationship. Disruption of intestinal microbiota homeostasis-called dysbiosis-has been associated with several diseases. Whether dysbiosis is a cause or consequence of disease initiation and progression still needs to be investigated in more depth. The aim of this book is to highlight recent advances in the field of microbiome research, which are now shaping medicine, and current approaches to microbiome-oriented therapy for gastrointestinal diseases. Dr. Rinaldo Pellicano Dr. Sharmila Fagoonee Guest Editors 517 $a3Ts in Gastrointestinal Microbiome Era 606 $aPublic health and preventive medicine$2bicssc 610 $aacute pancreatitis 610 $aAlzheimer's disease 610 $aauto-immunity 610 $aBacteroides ovatus 610 $aBifidobacterium adolescentis 610 $aceliac disease 610 $achronic pancreatitis 610 $acirrhosis 610 $aClostridium difficile 610 $acrohn's disease 610 $aculture 610 $aculturing of fecal microbiota 610 $adiabetes mellitus 610 $aDysbiosis 610 $aenteropathy 610 $aFaecalibacterium prausnitzii 610 $afecal microbiota 610 $afecal microbiota transplantation 610 $afeces donor 610 $aflow cytometry 610 $agastric microbiota 610 $agastrointestinal 610 $agluten 610 $agut 610 $agut microbiota 610 $agut permeability 610 $agut virome 610 $aHelicobacter pylori 610 $ahepatocellular carcinoma 610 $ahigh-throughput 610 $aIBS 610 $aIL-12p70 610 $aIL-6 610 $aIL-8 610 $ainfant gut 610 $ainflammatory bowel disease 610 $aintestinal flora 610 $aintestinal microbiology 610 $aintestinal permeability 610 $airritable bowel disease 610 $ametabolic syndrome 610 $ametabolomics 610 $amicrobiome 610 $amicrobiota 610 $amicrobiota-gut-brain axis 610 $amononuclear cells 610 $anecrotizing enterocolitis 610 $aneurodegenerative disease 610 $anext-generation sequencing 610 $apancreatic cystic neoplasms 610 $apancreatic diseases 610 $apancreatic ductal adenocarcinoma 610 $apersistent 610 $aprecision medicine 610 $aRuminococcus gnavus 610 $asequencing 610 $asteatosis 610 $atechnology 610 $atherapy 610 $atransient 610 $atransient receptor potential channel 610 $atype 1 diabetes 610 $aulcerative colitis 610 $aviability of bacteria 610 $azonulin 615 7$aPublic health and preventive medicine 700 $aPellicano$b Rinaldo$4edt$01303773 702 $aFagoonee$b Sharmila$4edt 702 $aPellicano$b Rinaldo$4oth 702 $aFagoonee$b Sharmila$4oth 906 $aBOOK 912 $a9910557505703321 996 $a3Ts in Gastrointestinal Microbiome Era: Technology, Translational Research and Transplant$93027201 997 $aUNINA